Article info
PDFExtended reports
Decrease of anti-cyclic citrullinated peptide antibodies and rheumatoid factor following anti-TNFα therapy (infliximab) in rheumatoid arthritis is associated with clinical improvement
- Correspondence to:
Professor G Valesini
Dipartimento di Clinica e Terapia Medica Applicata, Cattedra di Reumatologia, Università “La Sapienza”, V’le del Policlinico 155, 00161 Rome, Italy; guido.valesiniuniroma1.it
Citation
Decrease of anti-cyclic citrullinated peptide antibodies and rheumatoid factor following anti-TNFα therapy (infliximab) in rheumatoid arthritis is associated with clinical improvement
Publication history
- Accepted November 19, 2003
- First published September 10, 2004.
Online issue publication
September 10, 2004
Request permissions
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.
Copyright information
Copyright 2004 by Annals of the Rheumatic Diseases